These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 24479240)

  • 1. Protecting the public's health through the application integrity policy.
    Katz PR
    Food Drug Law J; 2010; 65(3):539-43, iii. PubMed ID: 24479240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revocation of Office of Generic Drug's interim policy statement on inactive ingredients. Food and Drug Administration, HHS. Notice.
    Fed Regist; 1999 Apr; 64(83):23340-1. PubMed ID: 10558498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA's role in making exclusivity determinations.
    Dickinson EH
    Food Drug Law J; 1999; 54(2):195-203. PubMed ID: 11758573
    [No Abstract]   [Full Text] [Related]  

  • 4. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA notifications. FDA's tentative approval for generic Tenofovir.
    AIDS Alert; 2008 Jan; 23(1):11-2. PubMed ID: 18572475
    [No Abstract]   [Full Text] [Related]  

  • 7. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.
    Kefalas CH; Ciociola AA
    Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA's role in administering the Hatch-Waxman Act.
    Malkin BJ
    Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575
    [No Abstract]   [Full Text] [Related]  

  • 10. Implementation of the biosimilar pathway: economic and policy issues.
    Grabowski H; Long G; Mortimer R
    Seton Hall Law Rev; 2011; 41(2):511-57. PubMed ID: 21739758
    [No Abstract]   [Full Text] [Related]  

  • 11. Protecting FDA's ability to protect public health.
    Taylor MR
    Food Drug Law J; 2006; 61(4):805-8. PubMed ID: 17180774
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA policy on unapproved drug products: past, present, and future.
    Chhabra R; Kremzner ME; Kiliany BJ
    Ann Pharmacother; 2005; 39(7-8):1260-4. PubMed ID: 15956239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA reform in Congress: FDA's concerns. Food and Drug Administration.
    James JS
    AIDS Treat News; 1996 Apr; (no 245):5-7. PubMed ID: 11363624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multisource drugs: implications and concerns in the geriatric population.
    Gerbino PP; Joseph AS
    Hosp Pharm; 1993 Feb; 28(2):96-8, 101-2. PubMed ID: 10125706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second thoughts: do the FDA's responses to a fatal drug trial and the AIDS activist community's doubts about early access to drugs hint at a shift in basic FDA policy?
    Lovell MC
    Food Drug Law J; 1996; 51(2):273-94. PubMed ID: 11820202
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA's fraud policy and ethical concerns.
    Lepore P
    Qual Assur; 1995 Mar; 4(1):8-11. PubMed ID: 8520868
    [No Abstract]   [Full Text] [Related]  

  • 17. Linking a policy on nonformulary drugs to the FDA's therapeutic-potential classification system.
    Poirier TI; Vorbach M; Bache T
    Am J Hosp Pharm; 1994 Sep; 51(18):2277-8. PubMed ID: 7801989
    [No Abstract]   [Full Text] [Related]  

  • 18. Surrogate endpoints and FDA's accelerated approval process.
    Fleming TR
    Health Aff (Millwood); 2005; 24(1):67-78. PubMed ID: 15647217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The United States Food and Drugs Administration approves a generic enoxaparin.
    Ofosu FA
    Clin Appl Thromb Hemost; 2011 Feb; 17(1):5-8. PubMed ID: 21159709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.